Biohaven's Novel FGFR3-Directed ADC with Proprietary TopoIx Payload, BHV-1530, Shows Clinical Activity and Confirmed Responses in FGFR3-Altered Urothelial and Head and Neck Cancers, Oral Presentation at ENA 2026
Phase 1 data presented in an oral plenary session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets
and
- Responders to BHV-1530 in UC included patients who
failed prior enfortumab vedotin plus pembrolizumab (EV+P) and oral FGFR tyrosine kinase inhibitors. All
responders remained on treatment at data cutoff, some beyond 6 months.
- BHV-1530 was well tolerated with no FGFR class
toxicities: no DLTs, treatment-related SAEs or deaths, and no ILD; no hyperphosphatemia,
nail dystrophy or central serous retinopathy.
-
Biohaven completed FDA Type C meeting in 4Q 2026 and plans to initiate a pivotal study evaluating BHV-1530 in FGFR3-altered tumors, starting with UC, expected to begin as early as 1H 2027 to support potential accelerated approval.
Among 10 efficacy-evaluable patients with activating FGFR3 alterations, treated with BHV-1530 at doses of 3.3 mg/kg or higher, 9/10 had a tumor reduction and 6 achieved a partial response (PR; confirmed or unconfirmed, by investigator assessment per RECIST v1.1; Figure 1). Responses were observed in tumors with FGFR3 mutations and fusions, including in 3 of 5 patients with UC and all 3 patients with HPV-positive HNSCC. All responders remained on treatment as of the data cutoff, some for more than 6 months.

In UC, where all patients had progressed on prior EV+P, partial responses occurred in 3 of 5 patients with FGFR3-altered tumors, including a patient who had also received a prior FGFR inhibitor. Tumor reductions were also observed in the 2 patients with FGFR3 wild-type tumors, including one partial response pending confirmation (Figure 2).


BHV-1530 was well tolerated across all dose levels in 30 patients, with no dose-limiting toxicities, treatment-related serious adverse events or treatment-related deaths. The most common adverse events, nausea (43%) and fatigue (37%), were all Grade 1 or 2. Hematological toxicity was mostly low grade and manageable. None of the toxicities that commonly limit FGFR inhibitor therapy (hyperphosphatemia, nail dystrophy or central serous retinopathy) were observed, and no interstitial lung disease (ILD) was reported. Pharmacokinetic data showed that BHV-1530 is highly stable in circulation, with free payload exposure below 1% of ADC exposure, and a half-life of 7 to 14 days that supports Q3W dosing.
FGFR3 is frequently altered or overexpressed in UC. Activating mutations or fusions, together with overexpression of the wild-type receptor, are found in about half of metastatic UC and in 70% to 80% of non-muscle-invasive bladder cancer, and are also seen in head and neck, lung and other solid tumors (Figure 4). Enfortumab vedotin plus pembrolizumab is now the first-line standard of care for advanced UC, but many patients eventually progress and options after progression remain limited. The only FDA-approved FGFR-targeted therapy for advanced UC is an oral pan-FGFR tyrosine kinase inhibitor (TKI), indicated only for previously treated patients whose tumors carry a susceptible FGFR3 alteration, which leaves patients whose tumors overexpress wild-type FGFR3 without a targeted option. Pan-FGFR TKIs also inhibit FGFR1, FGFR2 and FGFR4, and their labeled class effects include hyperphosphatemia, nail disorders, stomatitis and retinopathy, which often require dose interruptions or reductions. Resistance can also emerge through mutations in the kinase domain where these drugs bind. BHV-1530 is designed to bind FGFR3 on the tumor cell surface rather than inhibit its kinase, and is being studied in patients with and without FGFR3 alterations.
BHV-1530 takes a different approach to FGFR3 than approved pan-FGFR tyrosine kinase inhibitors, which block kinase signaling across the FGFR family (Figure 5). The investigational antibody-drug conjugate is designed to bind selectively to FGFR3 on the tumor cell surface and deliver its TopoIx payload inside the cell, with no detectable binding to FGFR1, FGFR2 or FGFR4 in preclinical studies.
About Study BHV1530-101
BHV1530-101 (NCT06874335) is a Phase 1, first-in-human, multicenter study of BHV-1530 as monotherapy and in combination with an anti-PD-1 antibody in adults with advanced solid tumors. Patients with UC, HNSCC or non-small cell lung cancer (NSCLC) were enrolled irrespective of FGFR3 alteration status, without a minimum FGFR3 expression threshold. Patients with other solid tumors were eligible if their tumors harbored an activating FGFR3 alteration.
About BHV-1530
BHV-1530 is an antibody-drug conjugate directed against FGFR3, a validated but underexploited target in
urothelial cancer and other FGFR3-driven cancers and is a first-in-class potential FGFR3-directed ADC
incorporating
About Biohaven
Biohaven Ltd. (NYSE: BHVN) is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Biohaven is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and preclinical programs include Kv7 ion channel modulation for epilepsy; MoDE™ and TRAP™ extracellular protein degradation for immunological diseases; and myostatin inhibition for neuromuscular and metabolic diseases, including obesity. For more information, visit www.biohaven.com.
Forward-Looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected timing, conduct, and outcomes of Biohaven's ongoing and planned clinical trials of BHV-1530, including the combination with cemiplimab under the clinical supply agreement with Regeneron, the potential therapeutic benefits, efficacy, safety, and tolerability of BHV-1530, and the timing of planned regulatory interactions and filings. The use of certain words, including "continue," "plan," "will," "believe," "may," "expect," "anticipate," "on track," "potential," and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors, including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable U.S. regulatory requirements; the potential commercialization of Biohaven's product candidates and the expected timing thereof; the potential for Biohaven's product candidates to be successful therapies; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations." The forward-looking statements are made as of the date of this news release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
MoDE and TRAP are trademarks of Biohaven Therapeutics Ltd.
Libtayo is a registered trademark of Regeneron Pharmaceuticals, Inc.
Investor Contact:
Jennifer Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
+1 (201) 248-0741
Media Contact:
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
+1 (312) 961-2502

View original content to download multimedia:https://www.prnewswire.com/news-releases/biohavens-novel-fgfr3-directed-adc-with-proprietary-topoix-payload-bhv-1530-shows-clinical-activity-and-confirmed-responses-in-fgfr3-altered-urothelial-and-head-and-neck-cancers-oral-presentation-at-ena-2026-302944663.html
SOURCE Biohaven Ltd.
BIOHAVEN (BHVN)
| Volume | ||
| Market Cap | ||
| 52 Week High | ||
| 52 Week Low |
Minimum 15 minutes delayed. Source: LSEG